DarioHealth Reports First Quarter 2017 Results

    Record Quarterly Revenues of $1.0 Million

    Sequential Quarterly Revenue Growth of 20%

    May 15, 2017

    CAESAREA, Israel, May 15, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the three month period ended March 31, 2017.

    DarioHealth

    First Quarter Highlights

    • Record revenues of $1,007,000, increased 77% compared to the first quarter of 2016
    • Sequential quarterly revenue growth of 20% over fourth quarter of 2016
    • 76% of quarterly revenues derived from test strips and other consumables
    • Gross profit of 10.5% as consumable strips made up greater percentage of revenue
    • 6,900 Dario™ Blood Glucose Monitoring System devices sold in the U.S.; reaching cumulative sales of more than 25,000 devices in the U.S.
    • Consumable strips growth of 20% over fourth quarter of 2016  

    Chairman and CEO of DarioHealth, Erez Raphael, commented, "We are encouraged by the fact in less than one year from launch in the U.S. we have reached 25,000 devices sold in the U.S. and surpassed $1 million of quarterly revenue with the progress of the razor blade model and its higher gross margins.

    "We are optimistic for the remainder of 2017 to bring an expansion of our platform availability in the United States to include Android, as well as wider insurance coverage. In addition, we are excited about several strategic partnerships, like Dominique Wilkins as a brand ambassador and others that are still in the works. We believe these alliances will lead to accelerated user growth and we expect to see revenue growth to continue in each sequential quarter, and wider market access leading to faster market penetration."

    First Quarter 2017 Results Summary

    Revenue for the first quarter ended March 31, 2017 was $1,007,000, a 77% increase from $568,000 in the first quarter ended March 31, 2016, and a 20% increase sequentially from the fourth quarter of 2016. The increase in revenues is mainly a result of continued market penetration into the United States and Australia.

    Revenues for the first quarter of 2017 included direct-to-consumer sales in the U.S., as well as direct-to-consumer and business partners' sales in Australia, and product sales to distributors in the U.S., Italy, Canada and the United Kingdom.

    Gross profit of $106,000 was recorded in the first quarter ended March 31, 2017, an increase of $208,000 compared to a gross loss of $102,000 in the first quarter of 2016. This represented a gross profit of 10.5% as consumable strips made up greater percentage of the revenues.

    Operating loss for the first quarter ended March 31, 2017 increased by $2.3 million to $4.2 million, compared to a $1.9 million operating loss in the first quarter ended March 31, 2016. This increase is mainly due to the increase in our direct sales and marketing expenses in the U.S. and Australia as well expenses related to stock based compensation to management.

    Financial income of $7.4 million was recorded in the first quarter ended March 31, 2017, compared to a financial expense of $445,000 in the first quarter ended March 31, 2016. This change was mainly due to reversing the warrant revaluation expense recorded in the fourth quarter of 2016, due to a price protection feature included in warrants issued to investors in March and August 2016. This price protection feature expired on March 8, 2017, and as a result we cancelled the liability related to these warrants by recording financing income of $7.4 million.

    Net profit attributable to holders of common stock increased by $5.6 million to $3.2 million in the first quarter of 2017, compared to a loss of $2.4 million in the first quarter of 2016. This was mainly attributable to the increase in financial income previously described.

    As of March 31, 2017, cash and cash equivalents totaled $2.8 million.  Subsequent to the end of the first quarter, on April 5, 2017, the Company closed a public offering of 1,450,000 shares, at a purchase price of $3.10 per share, for aggregate consideration of $3,840,000, net of issuance costs.

    DarioHealth will host a first quarter 2017 conference call today at 9:00am ET.

    Conference Call Details:

    Date: Monday, May 15, 2017

    Time: 9:00AM ET

    Dial-in Number: (866) 682-6100

    International Dial-in Number: (862) 255-5401

    Webcast: http://www.investorcalendar.com/IC/CEPage.asp?ID=175941

    Participants are recommended to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through May 29, 2017. To listen to the replay, dial (877) 481-4010 (domestic) or (919) 882-2331 (international) and use replay ID 10384. The webcast replay will be available through August 15, 2017.

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it describes expected alliances, states that it believes alliances will lead to user growth, states that it expects to see revenue growth continue, and when it makes statements about expectations of platform availability to include Android devices and wider insurance coverage which it believes will lead to faster market penetration.  Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

     

     

    CONSOLIDATED BALANCE SHEETS

    U.S. dollars in thousands



    March 31,


    December 31,



    2017


    2016



    Unaudited



    ASSETS










    CURRENT ASSETS:





    Cash and cash equivalents


    $               2,817


    $                1,093

    Short-term bank deposits


    235


    225

    Trade Receivables


    482


    226

    Inventories


    849


    888

    Other accounts receivable and prepaid expenses


    702


    504






    Total current assets


    5,085


    2,936






    LEASE DEPOSITS


    44


    35






    PROPERTY AND EQUIPMENT, NET


    856


    901






    Total assets


    $               5,985


    $               3,872







     

     


    CONSOLIDATED BALANCE SHEETS

    U.S. dollars in thousands (except stock and stock data)




    March 31,


    December 31,



    2017


    2016



    Unaudited








    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)










    CURRENT LIABILITIES:





    Trade payables


    $              1,484


    $             1,812

    Other accounts payable and accrued expenses


    1,240


    1,113






    Total current liabilities


    2,724


    2,925






    LIABILITY RELATED TO WARRANTS


    28


    7,488






    STOCKHOLDERS' EQUITY (DEFICIENCY)





    Common Stock of $0.0001 par value -

    Authorized: 160,000,000 shares at March 31, 2017 (unaudited)
      and December 31, 2016; Issued and Outstanding: 7,976,521
      and 5,713,383 shares at March 31, 2017 (unaudited) and
      December 31, 2016, respectively


    6


    6

    Preferred Stock of $0.0001 par value -

    Authorized: 5,000,000 shares at March 31, 2017 (unaudited)
      and December 31, 2016; Issued and Outstanding: None at
      March 31, 2017 (unaudited) and December 31, 2016


    -


    -

    Additional paid-in capital


    54,945


    48,413

    Accumulated deficit


    (51,718)


    (54,960)

    Total stockholders' equity (deficiency)


    3,233


    (6,541)






    Total liabilities and stockholders' equity (deficiency)


    $              5,985


    $        3,872

     

     

    CONSOLIDATED STATEMENTS OF COMPREHENSIVE PROFIT (LOSS)

    U.S. dollars in thousands (except stock and stock data)




    Three months ended

    March 31





    2017


    2016





    Unaudited



    Revenues


    $                1,007


    $            568



    Cost of revenues


    901


    670










    Gross profit (loss)


    106


    (102)



    Operating expenses:







    Research and development


    $                   469


    $            397



    Sales and marketing


    1,825


    519



    General and administrative


    2,017


    905



    Total operating expenses


    4,311


    1,821



    Operating loss


    (4,205)


    (1,923)










    Financial income (expenses), net:







    Revaluation of warrants


    7,460


    (432)



    Other financial expense, net


    (13)


    (13)










    Total financial income (expenses), net


    7,447


    (445)



    Net profit (loss)


    $             3,242


    $      (2,368)



    Deemed dividend related to Series A Preferred Stock exchange agreement


    $                     -


    $           455



    Net profit (loss) attributable to holders of Common Stock


    $             3,242


    $       (2,823)



    Net profit (loss) per share







    Basic and diluted profit (loss) per share


    $               0.45


    $        (0.77)



    Weighted average number of Common Stock used
      in computing basic and diluted net profit (loss) per share


    7,195,801


    3,652,474




     

     

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    U.S. dollars in thousands




    Three months ended

    March 31,



    2017


    2016



    Unaudited

    Cash flows from operating activities:





    Net profit (loss)


    $           3,242


    $          (2,368)

    Adjustments required to reconcile net profit (loss) to net cash used in operating activities:





    Stock-based compensation and Common Stock to service providers


    1,585


    324

    Depreciation


    44


    102

    Increase is trade receivables


    (256)


    -

    Decrease (increase) in accounts receivables and prepaid expenses


    (210)


    10

    Decrease (increase) in inventories


    39


    (404)

    Decrease in trade payables


    (328)


    (422)

    Decrease in deferred revenues


    -


    (23)

    Increase in other accounts payable and accrued expenses


    262


    244

    Change in fair value of warrants to purchase shares of Common stock


    (7,460)


    432






    Net cash used in operating activities


    (3,082)


    (2,105)

    Cash flows from investing activities:





    Maturity of (investment in) lease deposits


    (9)


    8

    Purchase of property and equipment


    -


    (35)






    Net cash used in investing activities


    (9)


    (27)






    Cash flows from financing activities:





    Proceeds from issuance of Common Stock and warrants, net of issuance cost


    4,816


    7,538

    Proceeds from exercise of options and warrants


    -


    190






    Net cash provided by financing activities


    4,816


    7,728






    Increase in cash and cash equivalents


    1,724


    5,596

    Cash and cash equivalents at the beginning of the period


    1,093


    2,671






    Cash and cash equivalents at the end of the period


    $           2,817


    $           8,267

    Non-cash investing and financing activities:





    Conversion of Series A Preferred Stock to Common Stock


    $                    -


    $           2,277






    Payment for directors under Salary Program


    $               183


    $                 51


     

    Public Relations
    Shmuel Herschberg
    DarioHealth Corp.
    +1-800-896-9062
    shmuel@mydario.com

    Investor Relations
    Rob Fink/Brett Mass
    Hayden IR
    +1-646-415-8972/646-536-7331
    DRIO@HaydenIR.com

     

      

    SOURCE DarioHealth Corp.


    print email rss